The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation.
phentermine for alertness usa phentermine fed ex no prescription |
"The FDA approval of Multaq is an important milestone in the management of atrial fibrillation or atrial flutter that demonstrates the commitment of sanofi-aventis to provide patients and physicians with important new medicines in therapeutic areas with significant healthcare needs," said Christopher A. |
LLC.
The ATHENA trial, which involved 4,628 patients with AF or AFL and more than 2,300 patients receiving Multaq on top of standard therapy, demonstrated a 24% reduction in time to first CV hospitalization or all-cause mortality (P<0.
tramadol detection celexa xanax wellbutrin drugs |
"The FDA approval of Multaq is an important milestone in the management of atrial fibrillation or atrial flutter that demonstrates the commitment of sanofi-aventis to provide patients and physicians with important new medicines in therapeutic areas with significant healthcare needs," said Christopher A. Atrial fibrillation is a complex disease that increases the risk of stroke up to five-fold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality. |
Serum creatinine levels increase by about 0. |
|
Multaq should not be given to patients who are or may become pregnant (Category X) or nursing. |
"
Multaq is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. |
About dronedarone (Multaq)
Multaq, discovered and developed by sanofi-aventis, is one of the major therapeutic innovations in patients with atrial fibrillation in the last twenty years. |
For full prescribing information, please visit http://products. Sanofi-aventis is listed in Paris and in New York . |
Multaq should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval. |
|
The efficacy and safety of Multaq 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq.
The ANDROMEDA and ATHENA trials were published in the New England Journal of Medicine (NEJM) respectively in 2008 and 2009. |
Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. LLC. |
Treatment with Multaq can be initiated in an outpatient setting. |
This unstable population corresponds to the population of the ANDROMEDA trial in which patients receiving dronedarone had a greater than 2-fold increase in mortality compared to placebo. |
5 million people in the European Union.
The efficacy and safety of Multaq 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq. |
|
Initiation of Multaq treatment is contraindicated in patients with severe heart failure (NYHA class IV) or NYHA Class II - III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. |
001) when compared to placebo, meeting the study's primary endpoint. |
5 million people in the European Union.
"It is exciting that Multaq will now be available as a treatment option for patients with paroxysmal or persistent atrial fibrillation or atrial flutter," said Stuart Connolly, M. |
In contrast, in ATHENA, all patients had a history of AF/AFL, and 71% of patients had no heart failure, 25% were NYHA class I or II, and only 4% were class III.
In patients with new or worsening heart failure, the suspension or discontinuation of Multaq should be considered. |
Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. "Sanofi-aventis’ commitment to research and development in this area is rewarded today, and we hope it will benefit many patients suffering from this disease. |
| S. |
This reduction was generally consistent across study subgroups based on baseline characteristics or medications. |
Sanofi-aventis is listed in Paris and in New York . |
Hypokalemia and hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. |
The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance.5 million people in the European Union. |
| The patients enrolled in ANDROMEDA had relatively severe heart failure and had been hospitalized, or referred to a specialty heart failure clinic for worsening symptoms.1mg/dL following Multaq treatment initiation. |
This unstable population corresponds to the population of the ANDROMEDA trial in which patients receiving dronedarone had a greater than 2-fold increase in mortality compared to placebo. |
Multaq is also contraindicated in second- or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), bradycardia <50 bpm, QTc Bazett interval greater than or equal to 500 ms and severe hepatic impairment. |
"We are pleased that the FDA has granted approval of Multaq for patients in a therapeutic area that has seen few new treatment options in the last twenty years," said Marc Cluzel, MD, Senior Vice President, Research and Development, sanofi-aventis.
About dronedarone (Multaq)
Multaq, discovered and developed by sanofi-aventis, is one of the major therapeutic innovations in patients with atrial fibrillation in the last twenty years. |
"
The landmark ATHENA trial evaluated the efficacy and safety of Multaq in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure). |